3 - 5 NOVEMBER 2020...Fu Wei Chief Executive Oﬃcer, CBC Group, China Bao Cai Senior Director,...

www.biopharmaproduction.com

Knowledge Partners:

3 - 5 NOVEMBER 2020Delivered Digitally

Brought to you by:

30+NEW SPEAKERS IN 2020

InteractiveSESSION FORMATS

VIP Access PASS FOR PHARMA & BIOTECH

VIEW THE AGENDA

VIEW THE AGENDA

VIEW THE AGENDA

Special Offer for China Pharmaceutical &

Biotech Companies*


CHINA & GLOBAL BIOPHARMA EXPERTS

Dr. Song RulinExecutive President, China

Pharmaceutical Innovation and

Research Development Association

(PhIRDA), China

NEW

Zhang YuPresident and CEO,

Aeon Therapeutics, China

NEW

Lisa ZhengExecutive Director, Cell Line

Development, Transcenta, China

NEW

Yin Nan PoDirector, Asia Supply Chain, Amgen,

China

NEW

John ZhangVice President, Manufacturing

Technology and Process

Development, BeiGene, China

NEW

Dr. Chris ChenChief Executive Officer,

WuXi Biologics, China

NEW

Li Jing RongSenior Vice President, Product

Development and Manufacturing,

CStone Pharmaceuticals, China

NEW

Zhang Zhe RuPresident, Head of CMC and

Manufacturing, I-MAB Biopharma,

China

Dr. Zhu JianweiProfessor and Director of MOE

Engineering Research Center of Cell

Engineering and Antibody, Shanghai

Jiaotong University; CEO and Chief

Scientist, Jecho Biopharmaceuticals,

China

NEW

Dr. Kerstin OtteProfessor, Institute of Applied

Biotechnology, Biberach University

of Applied Sciences, Germany

NEW

Yi JizuSenior Vice President, CMC &

Quality Operations, YZY Biopharma,

China

NEW

Liu XunPresident, Biomedicine

Development and Business Division,

Jiangsu Hengrui Medicine, China

NEW

Dr. Orit Aharonovitz Senior Director, Cell Line &

Process Development, Teva

Pharmaceuticals, Israel

NEW

Lynn YangManaging Director, Sequoia Capital,

China

NEW

Jerry SuChief Executive Officer,

Zhejiang Huahai Biopharmaceuticals

NEW

Xi ChenDirector, Cell Engineering,

Qilu Pharmaceuticals, China

NEW

Ma Yuan HuiExecutive Director, Preclinical

Science, Shanghai HaiHe

Pharmaceutical, China

NEW

Dr. Jill CaiVice President, Biologics Bioprocess

and Development, WuXi Biologics,

China

NEW

James LiCo-Founder and CEO,

JW Therapeutics, China

David ShaoPresident, Chief Executive Officer,

Yisheng Biopharma, China

NEW

Glenn HassanChief Finance Officer, Chief Business

Officer, CANbridge Pharmaceuticals,

China

NEW

Wu You LingChief Executive Officer,

Zhejiang Teruisi Pharmaceuticals,

China

Liu Dong LianVice President, Manufacturing,

TOT BIOPHARM, China

Dr. Pan ZhiweiSenior Director, Process

Development, Junshi Pharma, China

Frank YeSenior Vice President, Technical

Operations, Transcenta, China

Rani JarkasChairman, Cedrus Investments,

Hong Kong

NEW

Liang TangVice President, CMC Management,

WuXi Biologics, China

NEW

Dr. Song ZhiweiPrincipal Scientist, Bioprocessing

Technology Institute, Singapore

Eric ChangHead, Cell Line Development,

JHL Biotech, China

Fu WeiChief Executive Officer, CBC Group,

China

Bao CaiSenior Director, Manufacturing,

Bio-Thera Solutions, China

NEW

Dr. Karen LiuFounding Partner, 3E Bioventures

Capital, China

NEWNEW

NEW

13.00 Chairperson’s Opening Remarks

JOINT OPENING PLENARYJoint Plenary Sessions with 10th Annual Biomanufacturing and

2nd Annual Cell & Gene Therapy Manufacturing

13.10 KEYNOTE ADDRESS

China’s Big Leap Towards BioPharma 2030 – Innovation,

Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China

Pharmaceutical Innovation and Research Development

Association (PhIRDA), China


China’s Biological Facilities for the Future – WuXi’s Story

on Technology and Innovation

Dr. Chris Chen, Chief Executive Officer, WuXi Biologics,

China

14.10 Online Networking & Stretch Break

9th Annual Cell Line Development & Engineering Asia

Commences


Dr. Orit Aharonovitz, Senior Director, Cell Line & Process

Development, Teva Pharmaceuticals, Israel

THE STATE-OF-PLAY FOR CLD

14.30 OPENING KEYNOTE

Optimising Cell Line Development: Applications for

Furthering Biopharma R&D Strategy

• Partnerships and ventures for furthering biopharma

R&D capabilities and strategies



15.00 Enhancing Complex Protein Expression with Highly

Efficient Gene Integration Technology

Senior Representative from Lonza

NOVEL ADVANCES IN CLD TECHNIQUES & TECHNOLOGY

15.30 Novel Transposases in Accelerating Cell Line

Development

Dr. Claes Gustafsson, Chief Commercial Officer and

Co-Founder, ATUM, U.S.


16.20 Efficient Cell Lines and Technology Applications

Lisa Zheng, Executive Director, Cell Line Development,

Transcenta, China

16.50 Developing a New CLD Process from Ground-Up

• Navigating the complex landscape of strategies for

generating new cell lines

• From DNA to lead clones, what new technologies

and core instrumentation may impact future protein

expression and cell line development campaigns?

Mark Stockdale, Amalgamator of Business and Biology,

Solentim, U.K.

17.20 High-Throughput Cloning Screening and Performance

for Next-Generation Innovative Therapeutics

Ting Chen, Director, Alphamab Oncology, China

17.50 Expanding Beyond Traditional Monoclonal Antibodies in

Cell Line Development

• Use case for the generation of the highest titer

production cell lines in under 1 week

• A look at how pharma is moving cell line development

earlier in the therapeutic development timeline

• Delivering >99% monoclonality with every campaign

through optimizing your CLD workflow

Dr. John Proctor, Senior Vice President, Marketing,

Berkeley Lights, U.S.

18.20 End of Conference Day 1

DAY 1, TUESDAY 3 NOVEMBER 2020




13.10 Manufacturers’ Panel: New Therapies, New Tech and New Investments • New frontiers in drug development • What is the gap in quality and investment? • Embracing new tech and start-ups to drive progress • New therapeutics manufacturing, commercialisation

and global access • Biomanufacturing 4.0 – Where are we at? • DAL’s GAMP and licensing laws – How is it affecting

our business and what we can expect? • The GQCE framework – quality consistency and

better pricing

Panelists: Jerry Su, Chief Executive Officer, Zhejiang Huahai

Biopharmaceuticals, China Glenn Hassan, Chief Finance Officer, Chief Business

Officer, CANbridge Pharmaceuticals, China (tentatively confirming)

William Cao, Founder, Chairman & CEO, Gracell Biotechnologies Group, China


9th Annual Cell Line Development & Engineering Asia Resumes


ENGINEERING HOST CELL LINES, GENOMICS & CRISPR IN FOCUS

14.30 Advances in Glycosylation and Expression Vectors for Recombinant Proteins

Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

15.00 Enabling New Frontiers in Recombinant Protein Therapeutic Development: A Novel and Modular CHO Expression Platform

• Tackling the pressures on the CHO expression system to express complex proteins – new modules for addressing a range of issues such as translation/secretion bottlenecks, lead candidate selection, quality assessment and barcoding of the clonal production cell line using next generation sequencing

• Three case studies illustrating the modular approach for the production of a biosimilar, a vaccine and a monoclonal antibody

Dr. Igor Fisch, Chief Executive Officer, Selexis, Switzerland

15.30 CRISPR in Cell Line Development:

Applications of CRISPR in Rapid Development of Stable

Transgene CHO Cell Lines

Dr. Zhu Jianwei, Professor and Director of MOE

Engineering Research Center of Cell Engineering and

Antibody, Shanghai Jiaotong University; CEO and Chief

Scientist, Jecho Biopharmaceuticals, China


16.20 Advances in Single-Cell Genomics and RNA Sequencing

Tools for Effective CLD*

Session Reserved for Namocell

16.50 Next-Generation Cell Line Engineering for

Biopharmaceutical Production

• Advancing microRNA to optimize and boost

productivity of cell line growth

• Use cases and applications of CRISPR/Cas9-

mediated knockout for enhanced titre

• Identifying bottlenecks in CLD: a streamlined and

high-throughput approach

Dr. Kerstin Otte, Professor, Institute of Applied

Biotechnology, Biberach University of Applied Sciences,

Germany

17.20 Applications for Glycan Analysis Workflows and

Bioanalytical Proteins*

Senior Representative from ProZyme

17.50 Industry Panel: Utilising Platform Technologies for CLD

• Navigating the systems and various methods to

accomplish their goals; comparing and contrasting

tools

• Case study-focused

• Dealing with the flow and generation of high-

throughput data and information

• The Biopharma 4.0 paradigm for CLD: digital twins,

applications of big data and tech developments for

cell culture processes

Panelists:



Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals,

China

Eric Chang, Head, Cell Line Development, JHL Biotech,

China

Lisa Zheng, Executive Director, Cell Line Development,

Transcenta, China


DAY 2, WEDNESDAY 4 NOVEMBER 2020

CONFERENCE AGENDA






China’s Biopharma Capital Markets – Future Funds and

Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

13.40 Venture Capitals Roundtable:

Show Me the Drug

• Investment landscape of Chinese biopharma market

• Evaluating drug pipelines and development prospects

• Mergers, expansion and JVs – Where do we see

transactions picking up?

• Financing new plants, new therapeutics, product

launch and scaling-up operations – How do we

review?

• Manufacturing 4.0 – How do VCs and banks play a

part in modernising the value chain?

Panelists:

Rani Jarkas, Chairman, Cedrus Investments, Hong Kong

Judith Li, Partner, Lilly Asia Ventures, China

Dr. Karen Liu, Founding Partner, 3E Bioventures Capital,

China

Lynn Yang, Managing Director, Sequoia Capital, China

Dr. John Zhu, Partner, 6 Dimensions Capital, China


9th Annual Cell Line Development & Engineering Asia

Resumes


Dr. Song Zhiwei, Principal Scientist, Bioprocessing


OPTIMISING WORKFLOWS AND BIOPROCESSES

14.50 High-Throughput and Seamless Workflow Automation

in CLD

Dr. Jill Cai, Vice President, Biologics Bioprocess &

Development, WuXi Biologics, China

15.20 Integrated Cell Line Development Strategy in Whole

CMC Picture

• How to evaluate a CHO based expression systems?

• Can the cell line generation work be integrated with

other process?

• How to achieve cell lines with high quality and stability

under fast workflow?

Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals,

China

15.50 Accelerating CLD for Commercial Success

Dr. Pan Zhiwei, Senior Director, Process Development,

Junshi Pharma, China


16.40 Using CHO to Develop Biosimilars from Non-CHO Host

Cell Line

Eric Chang, Head, Cell Line Development, JHL Biotech,

China

17.10 A Fully Integrated Platform Approach for Highly-Quality

CLD

• Case study in Henlius’ in-house capabilities across

the entire biologics value chain spanning across:

- High-titer cell lines;

- Proprietary cell culture production; and

- Continuous manufacturing process for commercial

production

Senior Representative from Shanghai Henlius Biotech,

China

17.40 Panel Discussion: What’s Next in the Future of CLD&E

• What is the next thing in medicine that we will need to

produce?

• A look ATMPs, tissue generation, stem cells,

exosomes and more

• The landscape for CRISPR: how ready or willing is the

industry to use CRISPR for cell line engineering?

• Partnerships and ventures for furthering biopharma

R&D capabilities and strategies

Moderator:

Dr. Song Zhiwei, Principal Scientist, Bioprocessing


Panelists:

Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and

Antibody, Shanghai Jiaotong University; CEO and Chief

Scientist, Jecho Biopharmaceuticals, China

Dr. Kerstin Otte, Professor, Institute of Applied

Biotechnology, Biberach University of Applied Sciences,

Germany

Dr. Jill Cai, Vice President, Biologics Bioprocess &

Development, WuXi Biologics, China

18.20 End of Conference

DAY 3, THURSDAY 5 NOVEMBER 2020

CONFERENCE AGENDA


16.10 China’s Biological Facilities for The Future – Growth,

Innovation and Investments

• Understanding Chinese’s bioprocessing capacity –

which market and what pipeline

• Challenges and opportunities in innovative drug

development and manufacturing in China

• Insights on growth strategies and how to manage

risks associated with geography and product

development

Larry Zhang, Chief Executive Officer, CASI

Pharmaceuticals. China

16.40 Scaling Up the Commercial Production of mAb

Therapeutics in China

• China’s capacity outlook and how do we capitalize on

the mAb therapeutics markets

• Teruisi’s breakthrough of mAb’s tech transfer

and large-scale production in China while in-line

with international standards – challenges and key

learnings

• Manufacture showcase to improve cost and efficiency

Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi

Pharmaceuticals, China

17.10 WuXi “Factory of the Future” – A CMC Manufacturing

Case Study

• Process development and pilot manufacturing at

WuXi Biologics

• Case study sharing on WuXi’s facilities based on

disposable technologies

• Process and quality control best practices upon

extensive analytic testing

Dr. Liang Tang, Vice President, CMC Management, WuXi

Biologics, China


• New IND review procedure

• Understanding the CMC strategy of biologic

development for FDA and NMPA IND Fillings

Dr. Ma Yuan Hui, Executive Director, Preclinical Science,

Shanghai HaiHe Pharmaceutical, China

QUALITY MANAGEMENT & EFFICACY STANDARDS

15.40 Integrated CMC Platforms to Develop Robust

Downstream Process for Clinical Manufacturing

Dr. Zhang Zhe Ru, President, Head of CMC and

Manufacturing, I-MAB Biopharma, China


16.30 Ensure Uninterrupted Supply of Biological Drugs

• Challenges in the biopharma supply chain – long

manufacturing lead time, yield variability, testing and

quality assurance, CMC compliance, global footprint,

demand fluctuation

• Strategical and tactical elements of biopharma supply

chain management

• Supply chain integration best practices across

different functions to cater for global supply

• Key measures should pharmaceutical companies take

to improve connections with external supply chain

Yin Nan Po, Director, Asia Supply Chain, Amgen, China

17.00 Biopharma Quality Assurance Best Practices and PAT

Insights

• National standards for Chinese biological products

and current challenges in quality management

• Case study sharing on product stability and quality

assurance during biomanufacturing

• Quality system implementation and PAT compliance

standards – assessment, review and results

Dr. Yi Jizu, Senior Vice President, CMC and Quality

Operations, YZY Biopharma, China

17.30 Biomanufacturing Process Validation and Quality Risk

Management

• New process concepts of CQAs, CPPs, and QbDs

• Best practices on quality risk management in

bioprocess development

• Case study on Bio-Thera’s manufacturing process

quality control on the newest Humira biosimilar

Bao Cai, Senior Director, Manufacturing, Bio-Thera

Solutions, China


DAY 1, TUESDAY 3 NOVEMBER 2020 DAY 3, THURSDAY 5 NOVEMBER 2020DAY 2, WEDNESDAY 4 NOVEMBER 2020

13.00 Opening Address:

China’s Big Leap towards BioPharma 2030 – Innovation,





13.30 Keynote Address:

China’s Biologics Facilities for the Future – WuXi’s Story



China


10th Annual Biomanufacturing commences

BIOMANUFACTURING 2030 – CHINA’S GREAT LEAP

14.20 Trends in Pharma 4.0 Standards and China’s New Drug

Delivery Strategy

• Demand for capacity drives China’s biomanufacturing

expansion – is China on the fast track?

• Approval process for biologics – a US-China

comparison

• QbD and quality matrix for meeting regulatory

requirements

Dr. Liu Xun, President, Biomedicine Development and

Business Division, Jiangsu Hengrui Medicine, China

14.50 Debottlenecking and Process Optimisation in China

BioPharma Landscape

• Rate-limiting steps in China biopharma’s facilities and

what are the solutions

• Data, complexity and variability in biomanufacturing

• Advances in bioprocess monitoring and analytics, and

bioinformatics and computational biology in China

Dr. Simon Hsu, Senior Vice President, Technical

Operations, Henlius, China

15.20 The New Age of Smart Continuous Manufacturing as

Market Moves to Commercial

• Optimizing continuous process with fixed stainless-

steel facilities

• Speed-to-market and cost reduction strategies

utilizing fully continuous process development

• Case study on building a world-class continuous

manufacturing facility and quality system in China

Dr. Li Jing Rong, Senior Vice President, Product

Development and Manufacturing, CStone

Pharmaceuticals, China





13.30 Venture Capitals’ Roundtable:

Show Me the Drug

• Investment landscape in the Chinese biopharma

market






review?



Moderator:


Panelists:




China




10th Annual Biomanufacturing continues

GMP IMPLEMENTATION – THE MADE IN CHINA 2025 PLAN

14.40 Under Chinese New Drug Administration Law and

New Vaccine Law – Oversight and Implementation

on Commercial Bioprocess Development and Process

Performance Qualification

• Industry challenges and opportunities upon the

introduction of Chinese new vaccine law

• Overview of the manufacturing best practices

and process performance qualification in cGMP

environment

• Process scale-up and optimization within Shanghai

Zerun’s commercial production

Dr. John Zeng, Executive Vice President, Product

Development and Commercialization, Shanghai Zerun

Biotechnology, China

15.10 Impact of NMPA Reform on CMC Strategy at IND Stage

• Regulatory environment before reform – what

are the challenges and how it differs with global

standards

15.20 Tech Transfer Development for mAb Manufacturing

Productivity Optimization

• Creating a robust development platform utilizing

technologies for scalable and cost-efficient mAb

manufacturing process

• JHL’s efforts to develop a suitable manufacturing

process and technologies used

• Case study sharing on Asia’s largest single-use

bioprocessing technology-based modular biopharma

manufacturing facility – how is it being implemented

and how has it benefited the manufacturing process

development

Dr. Zack Zheng, Vice President, Process Development,

JHL Biotech, China


INNOVATIVE BIOPROCESS DEVELOPMENT

16.10 Glycosylation of Monoclonal Antibody and the

Manipulation

• Glycosylation manipulation + upstream PB-Hybrid

platform + ADC development

Liu Dong Lian, Vice President, Manufacturing, TOT

Biopharm, China

16.40 Vaccine Manufacturing Innovation

Dr. David Shao, President, Chief Executive Officer,

Yisheng Biopharma, China

17.10 Case Study:

Bio-Works’ 3rd Gen Agarose Resins to Purifying

Antibody-based Therapies Using A Different 3-step

Column Chromatography Approach

Dr. Bjorn Hammarberg, Business Development Asia,

Bio-Works, Sweden


13.00 Manufacturers’ Panel:

New Therapies, New Tech and New Investment

• New frontiers in drug development

• What is the gap in quality and investment?

• Embracing new tech and start-ups to drive progress

• New therapeutics manufacturing, commercialization

and global access

• Biomanufacturing 4.0 – Where are we at?

• DAL’s GAMP and licensing laws – How is it affecting

our business and what can we expect?

• The GQCE framework – Quality consistency and

better pricing

Confirmed Panelists:

Jerry Su, Chief Executive Officer, Zhejiang Huahai

Biopharmaceuticals, China

Glenn Hassan, Chief Finance Officer, Chief Business

Officer, CANbridge Pharmaceuticals, China (tentatively

confirming)

William Cao, Founder, Chairman & CEO, Gracell

Biotechnologies Group, China


10th Annual Biomanufacturing continues

FUTURE FACILITIES & SMART BIOMANUFACTURING

14.20 Manufacturing Technology Showcases – Improving Cost

and Efficiency

• Next gen manufacturing facilities design and

investment trends

• Smart automation case studies to increase facility

efficiency and cost optimization

• Intelligent bioreactors – advantages and benefits

Frank Ye, Senior Vice President, Technical Operations,

Transcenta, China

14.50 Manufacturing Technology – From Tech Transfer to Risk

Analysis and Migration Strategy

• Essential elements of tech transfer and leading to

successful validation and robust commercialization

• Best practices of a structured risk analysis, quality

management and migration strategy

• Case study on BeiGene’s new biologics

manufacturing facility in Guangzhou – technology

used from cell line development to manufacturing

Dr. John Zhang, Vice President, Manufacturing

Technology and Process Development, BeiGene, China


CONFERENCE AGENDA


Richard Wang, CEO, Fosun Kite Biotechnology, China

Dr Zhang Yu, President and CEO, Aeon Therapeutics,

China

James Li, Co-Founder and CEO, JW Therapeutics, China

More panellists to be confirmed

15.45 Finding the Market Growth

Richard Wang, CEO, Fosun Kite Biotechnology, China


16.40 Addressing the Next Wave of Innovations in Cell

Therapies

James Li, Co-Founder and CEO, JW Therapeutics, China

17.10 From Liquid to Solid Tumors, from Manual to Automatic

Manufacturing

Dr Zhang Yu, President and CEO, Aeon Therapeutics,

China

17.40 Chairperson’s Summary and End of Day 1

INVESTMENTS AND COMMERCIALISATION

14.30 Biotech Investors Roundtable: Financial Incentives,

Investments and Pricing

Panelists:

Kan Chen, Principal, Qiming Weichuang Venture Capital

Management, China


15.10 Commercialisation Models and Case studies of CAR-Ts

CLINICAL TRIALS AND SUPPLY CHAIN

15.40 Efficacy Evidence and Clinical Trials – How They

Affect Product Launch and Outcomes-Based Pricing

Arrangements


16.30 Clinical Drug Development for Cell and Gene Therapies –

How Ready Institutions Are?

17.00 Case Study of Manufacturing and Supply Chain

Challenge

17.30 Chairperson’s Summary and End of Day 3

DAY 1, TUESDAY 3 NOVEMBER 2020 DAY 3, THURSDAY 5 NOVEMBER 2020DAY 2, WEDNESDAY 4 NOVEMBER 2020

13.00 Opening Address:

China’s Big Leap towards BioPharma 2030 – Innovation,






China’s Biologics Facilities for the Future – WuXi’s Story



China

14:00 Online Networking & Stretch Break

2nd Cell & Gene Therapy Manufacturing commences

CHINA MARKET

14:20 Chairperson’s Opening Remarks

14:30 Next Generation Cellular Gene Therapeutics

Dr William Cao, Founder, Chairman and CEO, Gracell


15:00 Industry Panel:

Regulatory Pathways for Cell and Gene Therapies in the

Region, and China





13.30 Venture Capitals’ Roundtable:

Show Me the Drug

• Investment landscape in the Chinese biopharma

market






review?



Moderator:


Panelists:




China





TECHNOLOGY AND INNOVATION

14:20 Developments in Precision Manufacturing and Tailored

Therapies

15:00 Innovations in CAR T-Cell Technology Developments and

Manufacturing

For speaking enquiry, please contact

[email protected]

15:30 Solid Tumors Treatment with TCR-T Generation

Alex Liu, TCR Discovery and Early Development,

Cytovant Sciences, China


15:30 Accelerating CAR-T Development and Manufacturing

Yao Shuyuan, General Manager, Wuxi Apptech, China

16:15 Developing Cancer Gene Therapy

16:45 Use of Adenoviruses for Gene Therapy

17:15 Chairperson’s Summary and End of Day 2


13.00 Manufacturers’ Panel:

New Therapies, New Tech and New Investment

• New frontiers in drug development

• What is the gap in quality and investment?

• Embracing new tech and start-ups to drive progress

• New therapeutics manufacturing, commercialization

and global access

• Biomanufacturing 4.0 – Where are we at?

• DAL’s GAMP and licensing laws – How is it affecting

our business and what can we expect?

• The GQCE framework – Quality consistency and

better pricing


Jerry Su, Chief Executive Officer, Zhejiang Huahai

Biopharmaceuticals, China

Glenn Hassan, Chief Finance Officer, Chief Business

Officer, CANbridge Pharmaceuticals, China (tentatively

confirming)

William Cao, Founder, Chairman & CEO, Gracell







BRONZE SPONSOR:

GOLD SPONSORS:

SPONSORS

AND EXHIBITORS

EXHIBITORS:

MEDIA PARTNERS:

SPOTLIGHT SPONSOR:

Thought leadershipOffer keynotes and educational sessions to you audience

through live webinars or pre-recorded video broadcast with

automated reminders, Q & A sessions and polls to keep your

attendees engaged.

Position your company in the networking heart of this

event and create great connection with your attendees

For more information on digital sponsorship opportunities, please contact: Yvonne Leong, +65 6508 2489, [email protected]

Powerful Digital MatchmakingBuild valuable relationships with our intelligent matchmaking

tool, live chat and integrated 1:1 video calls.

Focused MetricsMeasurable exposure and trackable meetings generate great

ROI. Booth views, meeting requests, engagement rates – you’ll

have all the data you need.

Informa Data+Unique option for increased lead generation through retargeting

of our global proprietary database in social media.

Virtual BoothsOnline spaces with your brand identity, showcase your product

demos, live chat with audiences. Manage your own logo,

description video, collateral, staff profiles and more.

Accelerated Brand ExposureGain prominence with focused digital theatres in the lead up,

main conference days, and up to 3 months after the event with

our on-demand content modules.

Unrivalled Opportunity to Profile your Company


Delivered digitally to help manage travel and physical distancing

restrictions, the organising committee for 6th BDP China is delighted to

present an innovative and creative format for the event.

Repurposed to address the emerging and likely permanent shifts in

the Chinese biopharma industry, key leaders in the region will convene

online to discuss investment climate beyond 2020, technological

advancements, industry case studies, and partnerships and expansion

opportunities across key value chains.

With live-streaming sessions, smart networking windows and elevated

exhibition platforms at our virtual BDP China, join us as the industry

convenes at this highly anticipated annual gathering of biopharma

leaders.

BY INDUSTRY:

China/MNC Pharma & Biotech .................................................. 50%

CDMOs/CROs/CMOs ..................................................................... 25%

Tech Solution Providers .................................................................. 10%

Regulators, Healthcare Agencies & Associations ............... 5%

Scientific Research & Universities .............................................. 5%

Others ........................................................................................................ 5%

BY GEOGRAPHY:

China ........................................................................................................ 50%

Japan, Korea, HK, Taiwan ................................................................. 15%

Southeast Asia .................................................................................... 10%

USA ............................................................................................................ 10%

Europe ...................................................................................................... 10%

Other Region .......................................................................................... 5%

WHO WILL YOU MEET?

83000+

Unique

Pageviews

76

Countries

34000+

LinkedIn

Impressions

OUR

MARKETING AND

DIGITAL MEDIA

OUTREACH

ABOUT THE EVENT

Day 1 of Main Conference | Tuesday, 3 November 2020

KEYNOTE ADDRESSChina’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization

KEYNOTE ADDRESSChina’s Biological Facilities for the Future – WuXi’s Story on Technology & Innovation

Day 2 of Main Conference | Wednesday, 4 November 2020

Manufacturers’ Panel:New Therapies, New Tech & New Investments

Day 3 of Main Conference | Thursday, 5 November 2020

KEYNOTE ADDRESSChina’s Biopharma Capital Markets – Future Funds & Innovative Financing

Venture Capitals Roundtable: Show Me the Drug

• Biomanufacturing 2030 – the hottest shifts in

manufacturing in China

• Trends in Pharma 4.0 standards and China’s new drug

delivery strategy

• Industry case studies for commercial manufacturing

• The state-of-play for cell line development

• Applications for furthering biopharma R&D strategy

• Novel CLD platform technologies and tools

• Industry case studies for high-throughput screening and

performance

• Maneuvering the Chinese Market for Cell and Gene Therapies

• Addressing the next wave of innovations in cell therapies

• Smarty biomanufacturing and process optimization

• Manufacturing technology showcases – Improving cost and

efficiency

• Innovative bioprocess development

• Sustainable manufacturing and scalability

• Advancements in cell engineering techniques for complex

proteins

• CRISPR and genomics in focus

• Data-driven, accelerated, and next-generation CLD

• Industry Panel: Perspectives on utilising platform technologies

for CLD

• Managing cost and accelerating manufacturing process

• Latest CAR T-cell technology developments

• Facilities design and construction call therapies

• DAL’s New GAMP and Licensing Law – Implementation and

oversight

• QbD and Quality Matrix for meeting regulatory requirements

• Biomanufacturing process validation and quality risk

management

• Best practices and strategies in biopharma supply chain

integration

• Optimising workflows and bioprocesses

• Exploring the synergies between engineered host cells and

process development for commercial success

• Industry Panel: what’s next in the future of CLD&E

• Investment and commercialisation landscape

• Case studies on clinical trial landscapes and efficacy evidence

AGENDA AT-A-GLANCE


Early Bird RateRegister & pay before 11 September 2020

Normal RateRegister & pay after 11 September 2020

Individual Rate USD 595 USD 695

Group Rates (Price per Delegate)

5 or More USD 495 USD 595


Early Bird RateRegister & pay before 11 September 2020

Normal RateRegister & pay after 11 September 2020

Individual Rate USD 895 USD 995

Group Rates (Price per Delegate)



3 EASY WAYS TO REGISTER3 EASY WAYS TO REGISTERContact Miki Kong

Registration Enquiry Email

Website

+65 6508 2477

[email protected]


Informa Connect is a trading name of IBC Asia (S) Pte Ltd.

Connect with us:

REGISTER NOWDelegates who have successfully registered for the event will receive their Online Networking System (ONS) details to connect and network with other attendees nearer to the event date!

*Organisers reserved rights to accept/reject complimentary pass applications submitted, also to request specific job functions as described below. This is to ensure you gain maximum benefit from conference content and networking activities.

Brought to you by:


3 - 5 NOVEMBER 2020Delivered Digitally

Local China CompaniesInternational Companies – Outside China*International Companies with Global HQ Located Outside China

VIP ACCESS

FOR PHARMA

MANUFACTURERS

CHINA

PHARMACEUTICAL &

BIOTECH COMPANIES

ATTEND FOR FREE* (FOR SPECIFIC JOB TITLES ONLY)

WeChat Official Account

https://www.biopharmaproduction.com/pricing/

3 - 5 NOVEMBER 2020...Fu Wei Chief Executive Oﬃcer, CBC Group, China Bao Cai Senior Director,...

Documents

Transcript of 3 - 5 NOVEMBER 2020...Fu Wei Chief Executive Oﬃcer, CBC Group, China Bao Cai Senior Director,...